


To be the national and regional Centre of Excellence for facilitating discovery, process development and manufacturing of cellular-based therapeutics.


VALUE PROPOSITION

- 1 Integrated End-to-End Manufacturing Support
- 2 Phase-Appropriate GMP
- 3 Capital-Efficient Access to Specialised Infrastructure
- 4 Leverage on Established Network
- 5 Bridge to Regional Scale-Up & Commercialisation

CAPABILITIES



OPERATING MODEL



- The above exemplified models can be further modified to meet clients' needs.
- Abbreviations: ACM: Ancillary Materials; PA-GMP: Phase Appropriate-Good Manufacturing Practices

CERTIFICATIONS

 **Manufacturer's License for Finished Products for Specially Authorised Clinical Use**

 **GMP Certification for Manufacturing of Investigational Finished Products**

Reference:
<https://share.hsa.gov.sg/mop/DealersNoticesLicences>

FACILITY

1,450 sqm facility, comprising of:


- **14** GMP-compliant clean suites
- **4** translational laboratories
- **1** QC laboratory
- State-of-the-art equipment
- Located in close proximity to major hospitals across Singapore



PROCESS DEVELOPMENT PARTNER



Process Accelerator for Cell Therapy Manufacturing (PACTMAN)



This initiative enables deep process and assay development support for clients' projects.

INDUSTRY PARTNERS*

For technology access and training




CLIENTS / PARTNERS*



CLIENTS' PRODUCT PIPELINE*

Variety of Product Types, High-mix, Low Volume



ACTRIS is a programme of the Consortium for Clinical Research and Innovation, Singapore (CRIS) and supported by the Singapore Ministry of Health for its set-up and through the National Medical Research Council Office, MOH Holdings Pte Ltd under the NMRC RIE2025 ACTRIS Funding Initiative (MOH-001528).

For enquiries
business@actris.cris.sg

* Information listed are non-exhaustive.